Details for New Drug Application (NDA): 021204
✉ Email this page to a colleague
The generic ingredient in STARLIX is nateglinide. There are nine drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the nateglinide profile page.
Summary for 021204
Tradename: | STARLIX |
Applicant: | Novartis |
Ingredient: | nateglinide |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 60MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Dec 22, 2000 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 120MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Dec 22, 2000 | TE: | RLD: | Yes |
Expired US Patents for NDA 021204
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | STARLIX | nateglinide | TABLET;ORAL | 021204-002 | Dec 22, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | STARLIX | nateglinide | TABLET;ORAL | 021204-002 | Dec 22, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | STARLIX | nateglinide | TABLET;ORAL | 021204-001 | Dec 22, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | STARLIX | nateglinide | TABLET;ORAL | 021204-001 | Dec 22, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | STARLIX | nateglinide | TABLET;ORAL | 021204-001 | Dec 22, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | STARLIX | nateglinide | TABLET;ORAL | 021204-002 | Dec 22, 2000 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription